Jade Biosciences Inc.

Last updated September 27, 2026
Favorite this organization

Organization details

Legal name
Jade Biosciences Inc.
Former names
Aerovate Therapeutics, Inc.
Ownership
Public
Status
Active
SIC code
2834 — Pharmaceutical Preparations
Jurisdiction of incorporation
Delaware
Headquarters city
Waltham
Headquarters state / province
Massachusetts
Headquarters country
United States
Fiscal year end
December
Ticker symbol
JBIO
Primary stock exchange
Nasdaq

Identifiers

SEC CIK
0001798749
EIN
83-1377888

Board of directors

Follow this board

Chief executives

Tom Frohlich · Chief Executive Officer
Since April 2025
Timothy P. Noyes · CHIEF EXECUTIVE OFFICER
Until April 2025 · Former

Director election results

Annual meeting of June 8, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

Board connections

15 of this board's directors also sit on 45 other boards.

Network of Jade Biosciences Inc.'s board connections PepGen Inc. PepGen Inc. Janux Therapeutics Inc. Janux Therapeutics Inc... Oruka Therapeutics Inc. Oruka Therapeutics Inc... Sionna Therapeutics Inc. Sionna Therapeutics In... SpyGlass Pharma Inc. SpyGlass Pharma Inc. Tyra Biosciences Inc. Tyra Biosciences Inc. Viridian Therapeutics Inc. Viridian Therapeutics... Vor Biopharma Inc. Vor Biopharma Inc. ARS Pharmaceuticals Inc. ARS Pharmaceuticals In... Acrivon Therapeutics Inc. Acrivon Therapeutics I... Acumen Pharmaceuticals Inc. Acumen Pharmaceuticals... Artiva Biotherapeutics Inc. Artiva Biotherapeutics... Bicara Therapeutics Inc. Bicara Therapeutics In... Black Diamond Therapeutics Inc. Black Diamond Therapeu... Climb Bio Inc. Climb Bio Inc. Cogent Biosciences Inc. Cogent Biosciences Inc... Christopher W. Cain Christopher W. Cain Eric Dobmeier Eric Dobmeier Habib J. Dable Habib J. Dable Joshua Resnick Joshua Resnick Lawrence Otto Klein Lawrence Otto Klein Peter Evan Harwin Peter Evan Harwin Peter Kolchinsky Peter Kolchinsky Rajeev M. Shah Rajeev M. Shah Tomas Kiselak Tomas Kiselak Jade Biosciences Inc.
Shared director Other board Same sector +29 more in the list below

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months
$0
0 purchases by 0 insiders
Sold, last 12 months
$0
0 sales by 0 insiders
Date Insider Transaction Shares Price Value
Feb 12, 2026 Dahms Bradford D. Officer (Chief Financial Officer) Grant or award +37,813 — —
Feb 12, 2026 Balta Elizabeth Officer (See Remarks) Grant or award +28,125 — —
Feb 12, 2026 Tom Frohlich Director, Officer (Chief Executive Officer) Grant or award +78,750 — —
Feb 12, 2026 King Andrew James Officer (See Remarks) Grant or award +41,250 — —
Oct 6, 2025 Fairmount Healthcare Fund II L.P. Director, 10% owner Grant or award +1,333,126 $9.14 $12,184,772
May 16, 2025 Tom Frohlich Director, Officer (Chief Executive Officer) Open-market purchase +6,000 $7.40 $44,400
Apr 28, 2025 Peter Kolchinsky 10% owner Other +1,062,326 — —
Aug 1, 2024 Dake Benjamin T Officer (SEE REMARKS) Option exercise +1,507 $1.74 $2,622
Jul 31, 2024 Dake Benjamin T Officer (SEE REMARKS) Option exercise +11,454 $1.74 $19,930
Jun 17, 2024 Rajeev M. Shah Director, 10% owner Open-market purchase +928,110 $1.67 $1,549,944
Jun 14, 2024 Eldridge George A Officer (SEE REMARKS) Option exercise +15,000 $2.14 $32,100
Jun 14, 2024 Verwijs Marinus Officer (CHIEF TECHNICAL OFFICER) Option exercise +10,600 $14.59 $154,654
Jun 14, 2024 Eldridge George A Officer (SEE REMARKS) Open-market sale −15,000 $25.03 $375,450
Jun 14, 2024 Verwijs Marinus Officer (CHIEF TECHNICAL OFFICER) Open-market sale −10,600 $25.00 $265,000
Jun 13, 2024 Gillies Hunter Officer (CHIEF MEDICAL OFFICER) Option exercise +6,000 $2.14 $12,840

Reviews (0)

Sign in to write a review.

No reviews yet. Be the first to write one.

We use cookies to run this site and, with your permission, to measure traffic and support the affiliate links that help fund it.